Share on StockTwits

Stock analysts at Roth Capital assumed coverage on shares of Conatus Pharmaceuticals (NASDAQ:CNAT) in a report issued on Friday, reports. The firm set a “buy” rating and a $19.00 price target on the stock. Roth Capital’s target price would suggest a potential upside of 146.43% from the stock’s previous close.

Separately, analysts at Stifel Nicolaus cut their price target on shares of Conatus Pharmaceuticals from $16.00 to $14.00 in a research note on Friday, March 28th. Four equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $16.50.

Conatus Pharmaceuticals (NASDAQ:CNAT) traded up 4.02% during mid-day trading on Friday, hitting $8.02. The stock had a trading volume of 1,318,796 shares. Conatus Pharmaceuticals has a 52-week low of $5.06 and a 52-week high of $15.67. The stock’s 50-day moving average is $5.97 and its 200-day moving average is $8.17. The company’s market cap is $123.7 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.01. Analysts expect that Conatus Pharmaceuticals will post $-1.70 EPS for the current fiscal year.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of medicines to treat liver disease.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.